Lyell Immunopharma, Inc. (LYEL) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LYEL Revenue Growth
Revenue Breakdown (FY 2025)
LYEL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
LYEL Revenue Analysis (2019–2025)
As of May 8, 2026, Lyell Immunopharma, Inc. (LYEL) generated trailing twelve-month (TTM) revenue of $31,000, reflecting significant decline in growth of -71.4% year-over-year. The most recent quarter (Q1 2026) recorded $2,000 in revenue, down 66.7% sequentially.
Looking at the longer-term picture, LYEL's 5-year compound annual growth rate (CAGR) stands at -65.9%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $84.7 million in 2022.
Revenue diversification analysis shows LYEL's business is primarily driven by Reportable segment (100%). With over half of revenue concentrated in Reportable segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FATE (-51.2% YoY), ADCT (+4.4% YoY), and TGTX (+81.3% YoY), LYEL has underperformed the peer group in terms of revenue growth. Compare LYEL vs FATE →
LYEL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LYELCurrent | $31,000 | -71.4% | -65.9% | -566038.9% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 ADCT | $81M | +4.4% | - | -133.2% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
LYEL Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $36K | -41.0% | $-11,503,000 | -31952.8% | $-203,774,000 | -566038.9% |
| 2024 | $61K | -53.1% | $61K | 100.0% | $-358,755,000 | -588123.0% |
| 2023 | $130K | -99.8% | $130K | 100.0% | $-247,008,000 | -190006.2% |
| 2022 | $84.7M | +695.1% | $84.7M | 100.0% | $-187,058,000 | -220.9% |
| 2021 | $10.7M | +37.3% | $10.7M | 100.0% | $-214,776,000 | -2016.7% |
| 2020 | $7.8M | +1080.5% | $7.8M | 100.0% | $-211,937,000 | -2732.6% |
| 2019 | $657K | - | $657K | 100.0% | $-102,089,000 | -15538.7% |
See LYEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LYEL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LYEL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLYEL — Frequently Asked Questions
Quick answers to the most common questions about buying LYEL stock.
Is LYEL's revenue growth accelerating or slowing?
LYEL revenue declined -71.4% year-over-year, contrasting with the 5-year CAGR of -65.9%. TTM revenue fell to $31000.00. This reverses the prior growth trend.
What is LYEL's long-term revenue growth rate?
Lyell Immunopharma, Inc.'s 5-year revenue CAGR of -65.9% reflects the variable expansion pattern. Current YoY growth of -71.4% is below this long-term average.
How is LYEL's revenue distributed by segment?
LYEL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.